Patients with ER-positive breast cancer receive hormonal therapy using either selective estrogen receptor modulators (SERMs) such as tamoxifen, raloxifene and lasofoxifene, or with aromatase inhibitors (AIs) such as anastrozole, letrozole, and exemestene, and have a better prognosis. The gene discussed is ESR1; the disease is breast cancer.